[21] [22] Clinically, certain GLP-1 agonists have demonstrated cardiovascular benefits

However, there are critical distinctions: Rodents have a much higher density of GLP-1 receptors on thyroid C-cells than humans Human thyroid C-cells show minimal GLP-1 receptor expression No causal link between semaglutide and thyroid cancer has been established in human clinical trials involving over 10,000 participants (Bjerre Knudsen et al., 2010, Endocrinology ) A large pharmacovigilance study published in Diabetes Care found no increased risk of thyroid cancer among GLP-1 receptor agonist users compared to other diabetes medications (Bezin et al., 2023, Diabetes Care ) Despite this reassurance, the following patients should avoid semaglutide: Those with a personal history of medullary thyroid carcinoma (MTC) Those with a family history of MTC Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) For patients with common hypothyroidism (typically Hashimotos thyroiditis or post-surgical hypothyroidism), these contraindications do not apply

It is well established that triple-negative breast cancer (TNBC) is highly aggressive [22], with significantly higher rates of metastasis and recurrence compared to other breast cancer subtypes [23], especially in isceral and brain metastasis [24]
Among those who have been obese or overweight in past five years, 34% have used the medications and 23% are currently
Pregnant or breastfeeding women should also consult their doctor before using this medicine.
Powerful Antioxidant Blend: Features high-quality L-Carnitine and CoQ10 to help protect cells from oxidative stress and support healthy energy production